MOTS-c Peptide: Mitochondrial Research & Metabolism
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-08
A mitochondrial-derived peptide studied for insulin sensitivity and exercise-like metabolic effects
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA rather than the nuclear genome. Research has focused on its role in metabolic regulation, insulin sensitivity, and AMPK activation. It is not FDA-approved and human clinical data remains limited relative to its popularity in longevity and biohacking communities.
This article is for informational purposes only and is not medical advice. Consult a physician for medical guidance.
MOTS-c (short for Mitochondrial Open Reading Frame of the 12S rRNA type-c) is unusual among therapeutic peptides because of where it comes from: instead of being encoded by nuclear DNA like nearly every other peptide hormone, MOTS-c is encoded within the mitochondrial genome itself, inside the 12S ribosomal RNA gene. It was identified by researchers at the University of Southern California in the early 2010s as part of a small but growing class of “mitochondrial-derived peptides” (MDPs) that appear to let mitochondria communicate directly with the rest of the cell and with distant organs — a signaling role distinct from mitochondria's traditional job of producing cellular energy (ATP).
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →MOTS-c has no FDA-approved indication and is sold in the US only as a research chemical. Interest in it has grown quickly in longevity and performance circles because of its proposed connection to exercise physiology and metabolic health, but the human evidence base remains considerably smaller than the online discussion around it.
What the Research Shows
Animal studies are the foundation of the MOTS-c evidence base. In mouse models, MOTS-c administration has been associated with:
- Improved insulin sensitivity and better glucose uptake into skeletal muscle, including in models of diet-induced and age-related insulin resistance.
- Protection against diet-induced and age-related obesity in some mouse studies, with treated animals gaining less weight than controls on the same diet.
- Exercise-associated increases — circulating MOTS-c levels rise with exercise in both mouse and small human observational studies, which is part of why it has been described informally as an “exercise-mimetic” peptide, though that framing outpaces the current clinical evidence.
Human data is far more limited: most human studies to date are observational (measuring naturally circulating MOTS-c levels in relation to age, exercise, or metabolic status) rather than controlled trials of MOTS-c administered as a drug. No large randomized controlled trial establishing a standard human dose, safety profile, or clinical benefit has been published as of this writing. Circulating MOTS-c levels have also been observed to decline with age in some human cohort studies, which is part of why it draws interest in the longevity research community — but an association with age is not the same as evidence that supplementing it reverses age-related decline.
Proposed Mechanism
The leading hypothesis is that MOTS-c activates AMPK (AMP-activated protein kinase), a central cellular energy sensor that also responds to exercise, fasting, and metformin. AMPK activation shifts cell metabolism toward glucose uptake and fat oxidation and away from energy storage, which is the proposed basis for MOTS-c's studied effects on insulin sensitivity and body weight in animal models. Because AMPK is the same pathway targeted by metformin and activated by exercise, researchers have been interested in whether MOTS-c could reproduce some metabolic benefits of exercise pharmacologically — a hypothesis that remains unproven in humans.
Safety and Sourcing Considerations
MOTS-c has no established human safety database, no FDA-reviewed dosing standard, and no regulatory oversight of the “research chemical” products sold online under its name. As with other unregulated peptides, contamination, mislabeling, and inconsistent concentration are documented risks across this entire product category, independent of any specific finding about MOTS-c itself. Because much of the excitement around MOTS-c is tied to longevity and exercise-performance framing that outpaces the controlled-trial evidence, it's worth treating enthusiastic online claims with more skepticism than the underlying animal research actually supports.
Anyone considering MOTS-c should talk to a licensed physician first and understand it is being used entirely outside any approved medical framework. For more on how peptide sourcing and legal status work generally, see our guide on whether peptides are legal.
Frequently Asked Questions
What is MOTS-c peptide used for?
In research, MOTS-c has been studied for its role in metabolic regulation — particularly insulin sensitivity, glucose uptake into muscle, and body-weight regulation in animal models. It has no FDA-approved use, and most of this evidence comes from mouse studies rather than controlled human trials.
Is MOTS-c an exercise mimetic?
That's an informal description used in some research and popular coverage because circulating MOTS-c rises with exercise and activates AMPK, a pathway also engaged by physical activity. It is not an established, clinically validated substitute for exercise, and no human trial has demonstrated that MOTS-c reproduces exercise's benefits on its own.
Is MOTS-c legal and FDA-approved?
MOTS-c is not FDA-approved for any use. It is legally sold in the US only as a research chemical labeled “not for human use.” It is not a controlled substance, but that is different from being an approved, regulated medical product with an established human safety record.
How is MOTS-c different from other mitochondrial-derived peptides?
MOTS-c is one of several mitochondrial-derived peptides identified in recent years (others include humanin and small humanin-like peptides). What sets MOTS-c apart in the research literature is its specific association with metabolic and insulin-sensitivity effects, whereas other mitochondrial-derived peptides have been studied more for cell-survival and neuroprotective signaling.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Reading
-
AOD-9604 vs MOTS-c: Comparing Two Unproven Research Peptides
AOD-9604 vs MOTS-c: comparing two unproven research peptides with different target claims.